THE INVESTOR

메뉴열기
December 17, 2018

Samsung Bioepis to initiate phase 3 trials of Lucentis biosimilar

PUBLISHED : September 20, 2017 - 16:51

UPDATED : September 20, 2017 - 16:51

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Korea’s biopharmaceutical firm Samsung Bioepis is set to begin late-stage clinical trials of its copy version referencing Novartis’ eye drug Lucentis in Korea

The Ministry of Food and Drug Safety approved the initiation of phase 3 clinical trials of the biosimilar candidate SB11 on Sept. 18. 




The study will be conducted on 140 patients with wet age-related macular degeneration to compare efficacy and safety between SB11 and Lucentis. The brand name drug posted global sales of US$3.3 billion in 2016.

Lucentis has long been targeted by Korean bio startups like BIOCND and Polus, which jumped on the biosimilar bandwagon to make a copy.

To fend off the competition, Novartis has been pushing to expand indications of Lucentis.

In the latest upgrade, the US Food and Drug Administration approved the eye treatment for all forms of diabetic retinopathy in April.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.